Insulet Corporation Company Profile (NASDAQ:PODD)

About Insulet Corporation (NASDAQ:PODD)

Insulet Corporation logoInsulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Prosthetics
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:PODD
  • CUSIP: 45784P10
  • Web:
  • Market Cap: $2.97865 billion
  • Outstanding Shares: 57,916,000
Average Prices:
  • 50 Day Moving Avg: $48.42
  • 200 Day Moving Avg: $44.12
  • 52 Week Range: $30.69 - $52.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -376.86
  • P/E Growth: -4.29
Sales & Book Value:
  • Annual Revenue: $387.49 million
  • Price / Sales: 7.89
  • Book Value: $1.10 per share
  • Price / Book: 47.96
  • EBIDTA: $11.22 million
  • Net Margins: -6.81%
  • Return on Equity: -48.46%
  • Return on Assets: -6.57%
  • Debt-to-Equity Ratio: 5.30%
  • Current Ratio: 8.56%
  • Quick Ratio: 7.69%
  • Average Volume: 445,852 shs.
  • Beta: 1.55
  • Short Ratio: 9.89
Frequently Asked Questions for Insulet Corporation (NASDAQ:PODD)

What is Insulet Corporation's stock symbol?

Insulet Corporation trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet Corporation's earnings last quarter?

Insulet Corporation (NASDAQ:PODD) posted its earnings results on Monday, May, 8th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.01. The company had revenue of $101.70 million for the quarter, compared to analysts' expectations of $97.73 million. Insulet Corporation had a negative net margin of 6.81% and a negative return on equity of 48.46%. The business's revenue was up 25.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.19) earnings per share. View Insulet Corporation's Earnings History.

Where is Insulet Corporation's stock going? Where will Insulet Corporation's stock price be in 2017?

14 equities research analysts have issued twelve-month price objectives for Insulet Corporation's stock. Their predictions range from $38.00 to $52.00. On average, they expect Insulet Corporation's share price to reach $47.42 in the next year. View Analyst Ratings for Insulet Corporation.

What are analysts saying about Insulet Corporation stock?

Here are some recent quotes from research analysts about Insulet Corporation stock:

  • 1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (7/20/2017)
  • 2. Northland Securities analysts commented, "Regulatory Filings Falling into Place. With the FDA BLA formal submission expected next week, Spark has shifted its focus towards its MAA filing for Europe and pre-commercialization activities." (5/9/2017)
  • 3. Jefferies Group LLC analysts commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13% missed the +20% annual target reiterated just last Q. To this end, mgmt highlighted that a more important metric to pay attention to is the 15k total patient adds (vs. 13k in 2015) and the installed base grew by 15%. Despite 670G around the corner, Insulet remains largely dismissive of the launch." (2/28/2017)
  • 4. Wedbush analysts commented, " Insulet posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new management continues to fire on all cylinders with betterthan-expected revenues across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within the company's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017" (2/28/2017)

Who are some of Insulet Corporation's key competitors?

Who are Insulet Corporation's key executives?

Insulet Corporation's management team includes the folowing people:

  • Patrick J. Sullivan, Chairman of the Board, Chief Executive Officer
  • Shacey Petrovic, President, Chief Operating Officer
  • Michael L. Levitz, Chief Financial Officer, Senior Vice President, Treasurer
  • Bradley B. Thomas, Executive Vice President - Human Resources and Organizational Development
  • David Colleran J.D., Senior Vice President, General Counsel, Secretary
  • Aiman Abdel-Malek Ph.D., Senior Vice President - Advanced Technology and Engineering
  • Charles Alpuche, Senior Vice President - Global Manufacturing and Operations
  • Michael Spears, Senior Vice President - Quality and Regulatory Affairs
  • Bret Christensen, Chief Commercial Officer
  • Jessica Hopfield Ph.D., Lead Independent Director

Who owns Insulet Corporation stock?

Insulet Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rockefeller Financial Services Inc. (0.66%), KAMES CAPITAL plc (0.09%), Moreno Evelyn V (0.06%), Tributary Capital Management LLC (0.05%), Russell Investments Group Ltd. (0.05%) and Fisher Asset Management LLC (0.03%). Company insiders that own Insulet Corporation stock include Bradley A Thomas, Charles Alpuche, Daniel J Levangie, David A Lemoine, Jessica Hopfield, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan and Regina O Sommer. View Institutional Ownership Trends for Insulet Corporation.

Who sold Insulet Corporation stock? Who is selling Insulet Corporation stock?

Insulet Corporation's stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, OLD National Bancorp IN and Bank of Montreal Can. Company insiders that have sold Insulet Corporation stock in the last year include David A Lemoine, Joseph S Zakrzewski and Regina O Sommer. View Insider Buying and Selling for Insulet Corporation.

Who bought Insulet Corporation stock? Who is buying Insulet Corporation stock?

Insulet Corporation's stock was acquired by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Rockefeller Financial Services Inc., Russell Investments Group Ltd. and Diversified Trust Co. Company insiders that have bought Insulet Corporation stock in the last two years include Bradley A Thomas, Charles Alpuche, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet Corporation.

How do I buy Insulet Corporation stock?

Shares of Insulet Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insulet Corporation's stock price today?

One share of Insulet Corporation stock can currently be purchased for approximately $52.76.

MarketBeat Community Rating for Insulet Corporation (NASDAQ PODD)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  350 (Vote Outperform)
Underperform Votes:  305 (Vote Underperform)
Total Votes:  655
MarketBeat's community ratings are surveys of what our community members think about Insulet Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Insulet Corporation (NASDAQ:PODD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $47.42 (10.13% downside)

Analysts' Ratings History for Insulet Corporation (NASDAQ:PODD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/22/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
7/17/2017BTIG ResearchDowngradeBuy -> NeutralMediumView Rating Details
7/14/2017Cowen and CompanyReiterated RatingBuy$52.00MediumView Rating Details
7/14/2017Jefferies Group LLCReiterated RatingBuy$48.00LowView Rating Details
7/11/2017Canaccord GenuityReiterated RatingHold$42.00 -> $50.00LowView Rating Details
5/25/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
5/22/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$47.00LowView Rating Details
5/14/2017B. RileyReiterated RatingNeutral$44.00LowView Rating Details
5/9/2017Northland SecuritiesReiterated RatingBuy$50.00HighView Rating Details
2/28/2017WedbushBoost Price TargetOutperform -> Outperform$48.00 -> $50.00N/AView Rating Details
2/27/2017Feltl & Co.DowngradeBuy -> HoldN/AView Rating Details
1/6/2017Robert W. BairdUpgradeNeutral -> Outperform$39.00 -> $47.00N/AView Rating Details
11/17/2016J P Morgan Chase & CoReiterated RatingHold$38.00N/AView Rating Details
11/7/2016Leerink SwannReiterated RatingOutperform$55.00 -> $50.00N/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingNeutralN/AView Rating Details
2/26/2016Benchmark Co.UpgradeHold -> Buy$30.00 -> $40.00N/AView Rating Details
11/2/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$32.00N/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Insulet Corporation (NASDAQ:PODD)
Earnings by Quarter for Insulet Corporation (NASDAQ:PODD)
Earnings History by Quarter for Insulet Corporation (NASDAQ PODD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.16)($0.17)$97.73 million$101.70 millionViewListenView Earnings Details
2/27/2017Q416($0.05)($0.16)$100.61 million$103.58 millionViewListenView Earnings Details
11/3/2016Q316($0.09)($0.05)$89.75 million$94.90 millionViewN/AView Earnings Details
8/3/2016Q216($0.17)($0.08)$81.10 million$87.30 millionViewN/AView Earnings Details
4/28/2016Q116($0.19)($0.19)$79.06 million$81.21 millionViewListenView Earnings Details
2/25/2016Q415($0.26)($0.48)$91.89 million$100.10 millionViewListenView Earnings Details
11/5/2015Q315($0.26)($0.33)$83.56 million$87.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.27)$70.32 million$75.60 millionViewListenView Earnings Details
4/30/2015Q115($0.10)($0.21)$68.20 million$61.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.04)($0.10)$73.52 million$72.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.06)$72.94 million$72.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.06)($0.11)$68.47 million$69.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.04)$67.94 million$68.53 millionViewN/AView Earnings Details
11/7/2013Q313($0.16)($0.39)$62.01 million$61.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.20)$60.47 million$60.09 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.21)($0.20)$57.26 million$57.40 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.21)($0.21)$59.12 million$57.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)$54.93 million$54.80 millionViewN/AView Earnings Details
8/8/2012($0.25)($0.30)ViewN/AView Earnings Details
5/9/2012($0.28)($0.31)ViewN/AView Earnings Details
2/9/2012($0.26)($0.30)ViewN/AView Earnings Details
11/3/2011($0.25)($0.29)ViewN/AView Earnings Details
8/2/2011($0.21)($0.42)ViewN/AView Earnings Details
5/9/2011($0.22)($0.22)ViewN/AView Earnings Details
2/15/2011($0.26)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Insulet Corporation (NASDAQ:PODD)
2017 EPS Consensus Estimate: ($0.46)
2018 EPS Consensus Estimate: ($0.08)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20178($0.23)($0.10)($0.15)
Q2 20178($0.16)($0.04)($0.12)
Q3 20178($0.13)($0.02)($0.09)
Q4 20178($0.11)($0.02)($0.09)
Q1 20184($0.11)$0.02($0.05)
Q2 20184($0.11)$0.05($0.02)
Q3 20184($0.10)$0.06$0.00
Q4 20184($0.09)$0.06($0.01)
(Data provided by Zacks Investment Research)


Dividend History for Insulet Corporation (NASDAQ:PODD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Insulet Corporation (NASDAQ:PODD)
Insider Ownership Percentage: 2.60%
Insider Trades by Quarter for Insulet Corporation (NASDAQ:PODD)
Institutional Ownership by Quarter for Insulet Corporation (NASDAQ:PODD)
Insider Trades by Quarter for Insulet Corporation (NASDAQ:PODD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Michael P. SpearsSVPBuy2,500$40.59$101,475.00View SEC Filing  
5/11/2017Bradley A. ThomasEVPBuy3,000$38.69$116,070.00View SEC Filing  
5/11/2017Jessica HopfieldDirectorBuy2,580$38.68$99,794.40View SEC Filing  
5/1/2017David A. LemoineDirectorSell1,524$43.40$66,141.60View SEC Filing  
3/13/2017Regina O. SommerDirectorSell40,000$45.00$1,800,000.00View SEC Filing  
3/6/2017David A. LemoineDirectorSell1,282$45.15$57,882.30View SEC Filing  
3/2/2017Joseph S. ZakrzewskiDirectorSell40,000$46.86$1,874,400.00View SEC Filing  
12/9/2016Charles AlpucheSVPBuy6,600$37.70$248,820.00View SEC Filing  
12/2/2016Patrick J. SullivanCEOBuy40,000$33.89$1,355,600.00View SEC Filing  
12/1/2016Bradley A. ThomasEVPBuy3,100$32.45$100,595.00View SEC Filing  
5/25/2016Regina O SommerDirectorSell8,019$30.42$243,937.98View SEC Filing  
5/18/2016Patrick J SullivanCEOBuy45,000$27.00$1,215,000.00View SEC Filing  
5/13/2016Bradley A ThomasEVPBuy2,975$26.63$79,224.25View SEC Filing  
5/5/2016Bradley A ThomasEVPBuy1,656$30.13$49,895.28View SEC Filing  
3/10/2016Daniel J LevangieInsiderSell12,299$30.89$379,916.11View SEC Filing  
3/7/2016Daniel J LevangieInsiderSell7,663$31.15$238,702.45View SEC Filing  
3/2/2016Jessica HopfieldDirectorBuy3,230$30.91$99,839.30View SEC Filing  
6/5/2015Patrick J SullivanCEOBuy10,000$29.39$293,900.00View SEC Filing  
5/28/2015Patrick J SullivanCEOBuy20,000$27.91$558,200.00View SEC Filing  
5/15/2015Timothy J ScannellDirectorBuy3,500$27.05$94,675.00View SEC Filing  
5/5/2015Bradley A ThomasEVPBuy1,000$27.26$27,260.00View SEC Filing  
5/5/2015Patrick RyanCOOBuy3,669$26.99$99,026.31View SEC Filing  
4/2/2015R Anthony DiehlGeneral CounselSell3,372$30.96$104,397.12View SEC Filing  
3/9/2015Patrick J SullivanCEOBuy10,000$31.93$319,300.00View SEC Filing  
3/2/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
2/12/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
1/2/2015Charles T LiamosDirectorSell4,000$46.08$184,320.00View SEC Filing  
11/3/2014Charles T LiamosDirectorSell4,000$42.95$171,800.00View SEC Filing  
10/1/2014Charles T LiamosDirectorSell4,000$36.58$146,320.00View SEC Filing  
10/1/2014R Anthony DiehlGeneral CounselSell1,250$36.59$45,737.50View SEC Filing  
9/10/2014Charles T LiamosDirectorSell4,000$35.17$140,680.00View SEC Filing  
9/2/2014Duane DesistoCEOSell20,000$36.30$726,000.00View SEC Filing  
8/1/2014Duane DesistoCEOSell20,000$34.23$684,600.00View SEC Filing  
7/1/2014Duane DesistoCEOSell20,000$40.52$810,400.00View SEC Filing  
7/1/2014R Anthony DiehlGeneral CounselSell1,250$39.65$49,562.50View SEC Filing  
6/11/2014R Anthony DiehlGeneral CounselSell17,871$37.09$662,835.39View SEC Filing  
6/9/2014Peter DevlinInsiderSell12,314$37.10$456,849.40View SEC Filing  
4/8/2014Peter DevlinInsiderSell30,000$41.25$1,237,500.00View SEC Filing  
4/3/2014R Anthony DiehlGeneral CounselSell4,617$48.67$224,709.39View SEC Filing  
3/6/2014R Anthony DiehlGeneral CounselSell12,458$49.28$613,930.24View SEC Filing  
3/6/2014Tracey Haas WielinskiVPSell8,275$49.21$407,212.75View SEC Filing  
2/3/2014Charles LiamosDirectorSell11,037$42.93$473,818.41View SEC Filing  
2/3/2014Duane DesistoCEOSell20,000$42.95$859,000.00View SEC Filing  
2/3/2014Peter DevlinInsiderSell30,000$42.82$1,284,600.00View SEC Filing  
1/3/2014Charles LiamosCOOSell86,000$36.02$3,097,720.00View SEC Filing  
1/2/2014Duane DesistoCEOSell20,000$36.07$721,400.00View SEC Filing  
12/3/2013Charles LiamosCOOSell63,808$36.26$2,313,678.08View SEC Filing  
11/18/2013Charles LiamosCOOSell80,000$35.60$2,848,000.00View SEC Filing  
9/3/2013Duane DesistoCEOSell20,000$33.38$667,600.00View SEC Filing  
8/29/2013Sally CrawfordDirectorSell9,000$33.42$300,780.00View SEC Filing  
8/15/2013Regina SommerDirectorSell5,000$33.32$166,600.00View SEC Filing  
8/1/2013Duane DesistoCEOSell20,000$31.85$637,000.00View SEC Filing  
7/1/2013Duane DesistoCEOSell20,000$31.51$630,200.00View SEC Filing  
7/1/2013Peter DevlinInsiderSell30,000$31.48$944,400.00View SEC Filing  
6/14/2013Sally CrawfordDirectorSell31,000$30.47$944,570.00View SEC Filing  
6/10/2013R Anthony DiehlGeneral CounselSell38,455$30.50$1,172,877.50View SEC Filing  
6/3/2013Duane DesistoCEOSell20,000$29.76$595,200.00View SEC Filing  
12/3/2012Brian K RobertsCFOSell10,000$21.92$219,200.00View SEC Filing  
11/1/2012Brian K RobertsCFOSell10,000$21.49$214,900.00View SEC Filing  
9/4/2012Brian K RobertsCFOSell10,000$20.78$207,800.00View SEC Filing  
9/4/2012Duane DesistoCEOSell20,000$20.97$419,400.00View SEC Filing  
9/4/2012Ruthann DepietroVPSell1,000$20.90$20,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Insulet Corporation (NASDAQ:PODD)
Latest Headlines for Insulet Corporation (NASDAQ:PODD)
DateHeadline logoFinancial Contrast: Insulet Corporation (NASDAQ:PODD) & ReWalk Robotics (RWLK) - July 24 at 9:24 AM logoInsulet Corporation (NASDAQ:PODD) Rating Reiterated by Oppenheimer Holdings, Inc. - July 23 at 9:26 PM logoUpdates To Insulet Thesis: Innovation And Growth Continue - July 23 at 7:10 AM logoForm 8-K INSULET CORP For: Jul 20 - July 21 at 6:19 AM logoForm 8-K INSULET CORP For: Jul 20 - July 21 at 6:19 AM logoInsulet to Assume Distribution and Commercial Support for Its Omnipod ® System in Europe - July 21 at 6:19 AM logoInsulet to Assume Distribution and Commercial Support for Its Omnipod ® System in Europe - July 21 at 6:19 AM logoInsulet to Assume Distribution and Commercial Support for Its Omnipod® System in Europe - July 21 at 6:19 AM logoInsulet to Assume Distribution and Commercial Support for Its Omnipod® System in Europe - July 21 at 6:19 AM logoInsulet Corporation (NASDAQ:PODD) Lowered to Hold at Zacks Investment Research - July 20 at 11:26 PM logoAnalyzing Insulet Corporation (NASDAQ:PODD) & Delcath Systems (DCTH) - July 19 at 8:53 AM logoInsulet Downgraded Despite Expectations For Strong Performance - July 18 at 7:26 AM logoInsulet Corporation (NASDAQ:PODD) & Delcath Systems (DCTH) Head to Head Comparison - July 17 at 10:27 AM logoInsulet Corporation (NASDAQ:PODD) Lowered to Neutral at BTIG Research - July 17 at 9:58 AM logoInsulet Corporation (PODD) Earns "Buy" Rating from Jefferies Group LLC - July 15 at 3:35 PM logoCowen and Company Reiterates "Buy" Rating for Insulet Corporation (PODD) - July 15 at 8:14 AM logoInsulet Corporation to Announce Second Quarter 2017 Financial Results on August 3, 2017 - July 13 at 8:09 AM logoInsulet Corporation (NASDAQ:PODD) Rating Reiterated by Canaccord Genuity - July 11 at 7:44 AM logoHead-To-Head Review: Insulet Corporation (NASDAQ:PODD) & Delcath Systems (DCTH) - July 10 at 7:46 AM logoETFs with exposure to Insulet Corp. : July 7, 2017 - July 8 at 1:40 PM logoCritical Comparison: Delcath Systems (DCTH) & Insulet Corporation (PODD) - July 7 at 8:07 AM logoReviewing ReWalk Robotics (RWLK) & Insulet Corporation (NASDAQ:PODD) - July 6 at 10:08 AM logoInsulet Corporation (PODD) Expected to Announce Quarterly Sales of $106.05 Million - July 5 at 11:04 AM logoInsulet Corporation (NASDAQ:PODD) Receives Average Rating of "Buy" from Brokerages - July 4 at 12:32 AM logoInsulet Corporation (PODD) Expected to Post Earnings of -$0.13 Per Share - July 3 at 12:32 PM logoInsulet And Medtronic Join Investment In Glooko Diabetes Management - June 28 at 3:29 PM logoInsulet Corporation (PODD) Upgraded by BidaskClub to Strong-Buy - June 27 at 10:52 PM logoETFs with exposure to Insulet Corp. : June 26, 2017 - June 27 at 7:24 AM logoInsulet Corporation (PODD) versus Wright Medical Group N.V. (WMGI) Critical Analysis - June 25 at 7:37 AM logoJefferies Group LLC Reiterates "Buy" Rating for Insulet Corporation (PODD) - June 17 at 1:40 PM logoCritical Survey: Wright Medical Group N.V. (WMGI) and Insulet Corporation (PODD) - June 16 at 10:21 AM logoETFs with exposure to Insulet Corp. : June 15, 2017 - June 16 at 8:59 AM logoInsulet (PODD) Presents At The William Blair 2017 Growth Stock Conference - Slideshow - June 15 at 4:43 AM logoInsulet Corp. :PODD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 11:43 PM logoInsulet Corp. breached its 50 day moving average in a Bearish Manner : PODD-US : June 12, 2017 - June 12 at 6:56 PM logoInsulet Presents Positive Omnipod® Horizon™ Hybrid Closed-Loop Study Results in Children - June 12 at 8:02 AM logoInsulet to Preview New Clinical Data and Next Generation Omnipod® System at the American Diabetes Association’s 77th Scientific Sessions - June 10 at 8:48 AM logoInsulet Co. (PODD) Expected to Post Quarterly Sales of $106.07 Million - June 9 at 2:58 PM logoAscensia Diabetes Care Announces Strategic Alliance with Insulet Corporation to Connect CONTOUR(R)NEXT ONE BGMS and Omnipod Dash(TM) PDM - June 8 at 8:10 PM logoAscensia Diabetes Care Announces Strategic Alliance with Insulet Corporation to Connect CONTOUR®NEXT ONE BGMS and Omnipod Dash™ PDM - June 8 at 8:10 PM logo-$0.13 Earnings Per Share Expected for Insulet Co. (PODD) This Quarter - June 7 at 10:18 AM logoInsulet Co. (PODD) Receives Average Rating of "Buy" from Brokerages - June 7 at 12:45 AM logoHead-To-Head Contrast: DENTSPLY SIRONA (XRAY) & Insulet (PODD) - June 6 at 12:06 AM logoInsulet Corporation to Present at Upcoming Investor Conference - June 5 at 7:54 PM logoInsulet Co. (PODD) Lifted to Hold at ValuEngine - June 3 at 2:34 PM logoNew commercial chief at Insulet - May 30 at 6:59 PM logoInsulet Appoints Bret Christensen as Chief Commercial Officer - May 30 at 9:47 AM logoInsulet Co. Forecasted to Earn FY2017 Earnings of ($0.59) Per Share (PODD) - May 29 at 7:30 AM logoInsulet's (PODD) Hold Rating Reiterated at Canaccord Genuity - May 26 at 8:12 AM logoInsulet Co. (PODD) Sees Significant Growth in Short Interest - May 26 at 7:12 AM



Insulet Corporation (PODD) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by Staff